Biocryst Pharmaceuticals (BCRX) Non-Current Assets (2010 - 2026)

Biocryst Pharmaceuticals has reported Non-Current Assets for 17 years, with the latest figure at $91.4 million in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Assets rose 30.48% year-over-year to $91.4 million; the trailing twelve-month figure through Mar 2026 stood at $350.7 million (up 12.55% YoY), and the FY2025 full-year result was $109.8 million, up 60.42% from the prior year.
• Non-Current Assets for Q1 2026 stood at $91.4 million, down from $109.8 million in the prior quarter.
• The five-year high for Non-Current Assets was $109.8 million in Q4 2025, with the low at $15.7 million in Q2 2022.
• Historically, Non-Current Assets has averaged $51.6 million across 5 years, with a median of $49.6 million in 2022.
• Annual changes were most pronounced in 2023 — Non-Current Assets plunged 58.75% — and 2024, when it jumped 478.69%.
• Biocryst Pharmaceuticals' Non-Current Assets stood at $33.5 million in 2022, then slumped by 37.33% to $21.0 million in 2023, then jumped by 226.06% to $68.5 million in 2024, then soared by 60.42% to $109.8 million in 2025, then slipped by 16.74% to $91.4 million in 2026.
• The last three Non-Current Assets figures came in at $91.4 million (Q1 2026), $109.8 million (Q4 2025), and $90.7 million (Q3 2025), per Business Quant data.